3. Outcome matrix: opioids versus placebo for reviews contributing quantitative outcomes.

Events reported

Cepeda 2006

Chaparro 2012

Chaparro 2013

da Costa 2014

Derry 2016

Gaskell 2016

Haroutiunian 2012

McNicol 2013

Noble 2010

Santos 2015

Stannard 2016

Whittle 2011

Totals

Any adverse event

X

X

X

X

X

X

6

Any serious adverse event

X

X

X

X

X

X

6

Withdrawals due to adverse events

X

X

X

X

X

X

X

X

X

X

10

Deaths

X

X

X

X

X

X

X

X

X

9

Anorexia

X

1

Constipation

X

X

X

X

4

Diarrhoea

X

1

Dizziness

X

X

X

X

X

5

Drowsiness or somnolence

X

X

X

X

4

Fatigue

X

1

Gastrointestinal (unspecified)

X

1

Headache

X

1

Hot flushes

X

1

Increased sweating

X

1

Infection

X

X

2

Nausea

X

X

X

X

4

Nervous system (unspecified)

X

1

Pruritus

X

1

Sinusitis

X

1

Vomiting

X

X

X

3

Xerostomia

X

1

An "X" indicates that the outcome was reported (whether or not any participants experienced it).

In Cepeda 2006, "serious adverse events" were defined as adverse events that resulted in withdrawals. These data are therefore included in both categories for the review in question.